Fritextsökning
Artiklar per år
Innehållstyper
-
Västsvenska life science-aktörer rattar EU-projekt inom precisionsmedicin
Ett nytt projekt ska koppla samman innovationssystem i hela Europa för att få fart på implementeringen av precisionsmedicin. Och spindel i nätet är en rad tunga västsvenska life science-aktörer.
-
Tidigare Tobii-chef blir vd för Surgical Science
Tom Englund, tidigare toppnamn inom Tobii-koncernen, är nuvarande operativ chef för Instabee. Nu lämnar han budbolaget och återvänder till medicinteknikfältet när han blir vd för Surgical Science i oktober.
-
Nobel Prize winner Torsten Wiesel turns 100: “Old men like me should use their experience to help the young”
In 1955, a young Torsten Wiesel jumped on a boat to the US and embarked on a fabulous career as a neuroscientist, crowned with a Nobel Prize for his work. Now 100 years old, he looks back on an intense life and his upbringing in Stockholm, Sweden, which shaped his desire to help the vulnerable in society.
-
Innovative start-up helps doctors, scientists and industry balance coagulation risks
For many doctors caring for seriously ill patients, for example, in stroke units and cancer wards, maintaining the life-saving balance between bleeding and thrombosis is an ongoing challenge. In the late 1980s, scientists at Maastricht University in the Netherlands developed an innovative method, the thrombin generation assay (TGA), which provides a complete overview of a physiological process crucial for maintaining normal haemostasis.
-
“Conducting research at universities is becoming more and more like working at a research hotel”
The government wants Swedish research to focus on excellence and innovation, but can the two be combined? Life Science Sweden talks to Anna Falk, a professor at Lund University, about research policy, the constant hunt for funding in academia and what constitutes ‘fine research’.
-
Bayer has cut 1,500 roles – so far
German chemical and pharmaceutical group Bayer cut more than 1,500 roles in the first quarter alone– and most of them were management positions.
-
Carl Borrebaeck – professor and serial entrepreneur with a taste for speed
Award-winning cancer researcher, the founder of many listed companies, and constantly in the academic and commercial spotlight for decades. However, Carl Borrebaeck, Professor of Immunotechnology at Lund, is not yet satisfied. “We have a new, potentially super exciting project in the pipeline,” he says.
-
Björn Arvidsson: ”Vi måste börja se EU som inrikespolitik”
”Över hälften av alla lagar som stiftas i Sverige kommer från EU-politiken, vilket tydligt visar att förarbetet, möjligheten att påverka både oss och resten av unionen samt de viktiga besluten, sker utanför Sverige.” Det skriver Björn Arvidsson i en krönika.
-
Bakteriofager – ”Ett fält som står inför en pånyttfödsel”
För tio år sedan kallades fagterapi för ”det bortglömda botemedlet”. Men i takt med att antibiotikaresistens breder ut sig vinner den nygamla tekniken mer och mer mark i Europa. Life Science Sweden har pratat om framtiden med forskare som sysslar med antibiotikaresistens respektive bakteriofager.
-
Ancient DNA provides new insights – “The immune system lost its job”
Ancient bone remains from our ancestors have provided new insights into the prevalence of multiple sclerosis. By looking back in time, researchers can provide a possible explanation for why the disease is more prevalent in northern Europe.
-
Nocebo – the evil twin that makes you feel worse
The placebo effect is well known in healthcare, but not so its opposite: nocebo. “The effect is small, but it can have major repercussions,” says Uppsala researcher Charlotte Blease, co-author of a book on the phenomenon.
-
Anställningsstopp och nedskärningar i Region Dalarna
Sedan tidigare står det klart att en tredjedel av tjänsterna inom vårdnära service försvinner i Region Dalarna. Nu har regionstyrelsen också beslutat om ett generellt anställningsstopp för att kämpa mot ett växande underskott.
-
Study: Popular diabetes treatment is not associated with thyroid cancer
Concerns raised about an association between GLP-1 analogues, used to treat diabetes and obesity, and an increased risk of thyroid cancer are not supported by an extensive Scandinavian study.
-
The life science strategy – what the industry wants
The process of updating the national life science strategy has begun at the government’s life science office. According to industry stakeholders, Sweden’s competitiveness, the accessibility of health data and the integration of innovation in healthcare
-
Efter miljardköpet – nu sparkas 250 av bolagets anställda
Läkemedelsjätten Bristol Myers Squibb betalade nästan sex miljarder dollar för Mirati Therapeutics. Nu – två månader senare – gör man sig av med över 250 av biotechbolagets anställda.
-
Anna Törner: ”Orphan Designation – the "petite robe noire" of drug development”
It is easy to cling to various regulatory incentives, like orphan designation, and other expedited pathways, without understanding what they truly mean or whether they are indeed right (or wrong) for the current project, Anna Törner writes in a column.
-
Specific proposals and targets top the universities’ desired priorities
What are the universities’ expectations for the update of the national life science strategy? Life Science Sweden posed the question to representatives from Karolinska Institutet and Sahlgrenska Academy.
-
“What is important is to create an overview and understanding from different perspectives”
Scientist Jochen Schwenk analyses blood proteins using proteomics to improve our understanding of disease and health. This year, he is moderating the Lab & Diagnostics of the Future event.
-
From Valneva to the CEO position at NorthX – “I saw it as a great opportunity”
A new cell therapy for leukaemia, a vaccine in tablet form against cholera, and a proprietary mRNA line with the potential capacity to supply the entire Nordic region with vaccines during a future pandemic. These are some of the projects underway at NorthX Biologics – under the direction of new CEO Janet Hoogstraate.
-
To build trust, one must be able to say “I don’t know” – whether human or AI
Will AI strengthen or break down trust? It depends on whether we can understand and accept its limitations, and our own, writes Sarah Lidé in a column.
-
Elon Musk: Första Neuralink-patienten kan styra dator med tanken
Den första patienten som har fått ett hjärnchip från Neuralink inopererat kan nu flytta en muspekare – enbart genom att tänka. Det uppgav det spektakulära projektets grundare Elon Musk på måndagen.
-
Forskare kan ha utvecklat världens första blodprov för hjärncancer
Forskare i Storbritannien säger sig ha utvecklat ett blodprov för hjärncancer – något som aldrig tidigare funnits. Nu väntar ytterligare studier.
BREAKING